Fenrock (fentanyl transdermal)
/ Filana Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 18, 2019
Modelling the potential impact of abuse-deterrent opioids on medical resource utilization.
(PubMed, J Med Econ)
- "Replacement of transdermal fentanyl is associated with the smallest amount of cost savings and lowest number of avoided medical events. Agonist/antagonist abuse-deterrent opioid technology is associated with higher annual medical cost savings and more avoided events than physical/chemical barrier technology. Total net savings are dependent upon the abuse-deterrent opioid price relative to non-abuse-deterrent opioids."
HEOR • Journal
1 to 1
Of
1
Go to page
1